Keros Therapeutics
(NASDAQ) KROS
Keros Therapeutics Financials at a Glance
Market Cap
$233.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$33.18M
Net Income (TTM)
-$85.15M
EPS (TTM)
-$3.01
P/E Ratio
-3.93
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Price
$11.78
Volume
259,092.039
Open
$12.03
Price
$11.78
Volume
259,092.039
Open
$12.03
Previous Close
$11.80
Daily Range
$11.13 - $12.19
52-Week Range
$9.69 - $22.55
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Price
$11.78
Volume
259,092.039
Open
$12.03
Previous Close
$11.80
Daily Range
$11.13 - $12.19
52-Week Range
$9.69 - $22.55
Estimated Earnings Date
Aug 5, 2026
KROS News
KROS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Keros Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
78
CEO
Jasbir S. Seehra, PhD
Website
www.kerostx.comHeadquarters
Lexington, MA 02421, US
KROS Financials
Key Financial Metrics (TTM)
Gross Margin
96.48%
Operating Margin
-332.55%
Net Income Margin
-256.60%
Return on Equity
-17.04%
Return on Capital
22.07%
Return on Assets
-27.26%
Earnings Yield
-25.45%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$233.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
19.79M
Volume
259.09K
Avg. Volume
315.92K
Financials (TTM)
Gross Profit
$32.01M
Operating Income
-$110.35M
EBITDA
-$88.74M
Operating Cash Flow
-$57.20M
Capital Expenditure
-$1.06M
Free Cash Flow
-$58.25M
Cash & ST Invst.
$281.50M
Total Debt
$16.31M
Keros Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$367.00K
-99.8%
Gross Profit
-$36.00K
-100.0%
Gross Margin
-9.81%
N/A
Market Cap
$233.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$1.43M
N/A
Employees
163
N/A
Net Income
-$23.71M
-116.0%
EBITDA
-$23.31M
-114.7%
Quarterly Fundamentals
Total Cash
$281.50M
-60.9%
Total Debt
$16.31M
-11.4%
Accounts Receivable
$2.96M
-84.7%
Inventory
$0.00
N/A
Long Term Debt
$13.81M
-15.3%
Short Term Debt
$2.50M
+19.0%
Return on Assets
-27.26%
N/A
Return on Invested Capital
-36.85%
N/A
Free Cash Flow
-$3.60M
-102.2%
Operating Cash Flow
-$3.53M
-102.2%